Dr. Oliver P. Peoples, Ph.D.
President and Chief Executive Officer
Oliver P. Peoples, Ph.D. was named President and Chief Executive Officer of Metabolix in October 2016 in conjunction with the transition to Yield10 Bioscience as the Company's core business. Dr. Peoples was a co-founder of Metabolix and served as our Chief Scientific Officer from January 2000 until October 2016, and was previously our Vice President of Research and Development. Dr. Peoples has served as a director since June 1992. Prior to founding Metabolix, Dr. Peoples was a research scientist with the Department of Biology at the Massachusetts Institute of Technology where he emerged as a pioneer of the new field of metabolic pathway engineering and its applications in industrial biotechnology. The research carried out by Dr. Peoples at MIT established the fundamental tools and methods for engineering bacteria and plants to produce Mirel biopolymers. Dr. Peoples has published numerous peer reviewed academic papers and is an inventor of over 90 patents and patent applications worldwide. Dr. Peoples received a Ph.D. in Molecular Biology from the University of Aberdeen, Scotland.
KRISTI SNELL, PH.D.
Vice President, Research and Chief Science Officer
Kristi Snell, Ph.D. was named Vice President, Research and Chief Science Officer in October 2016 in conjunction with the transition to Yield10 Bioscience as the Company's core business. Dr. Snell joined Metabolix in 1997 and she has led the plant science research program since its inception. She has held a number of positions with the Company, including Vice President, Research and Biotechnology from July 2013 until October 2016 and President of Metabolix Oilseeds, Metabolix's wholly owned Canadian subsidiary, from April 2014 to present. Dr. Snell has more than 20 years of relevant experience and is an industry recognized expert in metabolic engineering of plants and microbes for the production of novel products and increased plant yield. Dr. Snell received a bachelor of science degree in Chemistry from the University of Michigan, and a Ph.D. in Organic Chemistry from Purdue University where she worked on metabolic engineering strategies to increase carbon flow to industrial products. Dr. Snell conducted her post-doctoral research at MIT in biochemistry and metabolic engineering.
Charles B. Haaser
Chief Accounting Officer
Charles B. Haaser was named Vice President, Finance and Chief Accounting Officer in October 2016 in conjunction with the transition to Yield10 Bioscience as the Company's core business. Mr. Haaser joined Metabolix in 2008 as Corporate Controller, and was named Chief Accounting Officer in November 2014. Mr. Haaser has more than thirty years of experience in accounting and finance, primarily working for publicly traded U.S. companies. Before joining Metabolix, Mr. Haaser was the Corporate Controller of Indevus Pharmaceuticals, Inc. from 2006 to 2008. He was the Corporate Controller and Principal Accounting Officer at ABIOMED, Inc. from 1998 to 2006 and additionally served as ABIOMED's Acting Chief Financial Officer from 2003 to 2006. From 1997 to 1998 Mr. Haaser was controller for Technical Communications Corporation and from 1986 to 1997 was the Director of Finance at ISI Systems, Inc. Prior to that, Mr. Haaser was an auditor in the commercial audit division of Price Waterhouse LLP (now PricewaterhouseCoopers LLP). Mr. Haaser received a bachelor's degree in business administration (finance) from the University of Notre Dame, an M.B.A. from Northeastern University and an M.S. in taxation from Bentley University. Mr. Haaser became a Certified Public Accountant in 1997.
LYNNE H. BRUM
Vice President, Planning and Corporate Communications
Lynne H. Brum was named Vice President, Planning and Corporate Communications in October 2016 in conjunction with the transition to Yield10 Bioscience as the Company's core business. Ms. Brum joined the company in November 2011 as Vice President, Marketing and Corporate Communications. Prior to joining Metabolix, in 2010 to 2011 she was a communications consultant and served in various roles including as a freelance project director for Seidler Bernstein Inc. Ms. Brum served from 2007 to 2009 as an Executive Vice President at Porter Novelli Life Sciences, a subsidiary of global PR firm, Porter Novelli International. Prior to that, Ms. Brum was responsible for corporate communications, investor relations and brand management for Vertex Pharmaceuticals, Inc. from 1994 to 2007 in various positions, including Vice President of Strategic Communications. Ms. Brum was also a vice president at Feinstein Kean Healthcare and was part of the communications team at Biogen, Inc. (now Biogen Idec). Ms. Brum holds a bachelor's degree in biological sciences from Wellesley College and an M.B.A. from Simmons College's School of Management.